Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc. (ORGS) generates frequent news as a global biotech company focused on cell and gene therapies (CGTs) and a decentralized approach to cell processing. News about the company often highlights progress on its therapeutic pipeline, developments in its decentralized platforms, and key financing and strategic agreements that shape its business trajectory.
Recent announcements include positive real-world study results for ORG-101, a CD19 CAR-T therapy for patients with CD19+ Acute Lymphoblastic Leukemia, along with plans to initiate Phase 1/2 multicenter clinical studies at hospitals in Greece supported by an Enterprise Greece grant. Orgenesis has also reported the acquisition of GMP-validated platforms for producing CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes, which it integrates into its decentralized production model.
News coverage also follows Orgenesis’ corporate and strategic moves. The company has announced a joint venture with Harley Street Healthcare Group to develop wellness and longevity services and products, including immune cell banking and regenerative therapies. It has reported a strategic collaboration to manufacture, co-market, distribute, and service its Orgenesis Mobile Processing Units and Labs (OMPULs), as well as partnerships and grants that support decentralized production of Advanced Therapy Medicinal Products and therapeutic exosomes.
Investors and observers can also track financing developments, such as equity investments, an equity line of credit with Williamsburg Venture Holdings, and a Convertible Loan Agreement involving Theracell, an indirect subsidiary. Trading venue updates, including a reverse stock split and the transition from Nasdaq to the OTCQX Best Market under the ORGS symbol, are additional recurring topics. This news page aggregates these earnings updates, clinical milestones, partnership announcements, financing transactions, and regulatory disclosures in one place for ongoing monitoring.
Orgenesis reports a substantial revenue increase in 2021, reaching $35.5 million, up from $7.7 million in 2020. The company has secured over $30 million in future commitments for 2022 and $55 million for 2023. Their POCare Platform aims to provide cost-effective cell and gene therapies at the point-of-care, addressing high costs and availability issues.
Recent developments include operational centers in multiple countries and a €32 million government grant in Greece, enhancing their capacity and market presence.
Orgenesis Inc (NASDAQ: ORGS) will host a conference call on March 30, 2022, at 12 PM ET to discuss its 2021 fiscal year financial results and corporate developments. The call can be accessed by U.S. callers at 888-506-0062 or internationally at +1 973-528-0011, using entry code 863051. A replay will be available for one hour post-call, and a webcast will also be available on their Investor Events section. Orgenesis, focused on cell and gene therapies, emphasizes its POCare Platform for affordable patient treatments worldwide.
Orgenesis (NASDAQ: ORGS) has successfully placed its first Orgenesis Mobile Processing Unit and Lab (OMPUL) in Europe at the Hospital Infantil Universitario Niño Jesús in Madrid, marking a key milestone in their collaboration. The OMPUL is designed for processing Tumor Infiltrating Lymphocytes (TILs) and Mesenchymal Stem Cells (MSCs). Its operational capability is expected to reduce development and manufacturing costs significantly for cell therapies, including the Celyvir therapy. This initiative aligns with Orgenesis' goal to enhance access to cell and gene therapies at the point of care.
Orgenesis Inc. has announced a partnership with Johns Hopkins University to launch a cell and gene therapy processing facility in Maryland. The project, supported by a $5 million grant from the state, aims to enhance point of care capabilities and is expected to become operational by Q2 2023. The new 7,000-square-foot facility will streamline treatment processes and reduce reliance on outsourcing by connecting with Orgenesis Mobile Processing Units. The center will house 30 Orgenesis employees and expedite clinical trials for innovative therapies.
Orgenesis (NASDAQ: ORGS) announced that its joint venture (JV) with Theracell in Greece has been designated a “Priority Investment of Strategic National Importance” by the Greek government. This status allows the JV to enter a fast-track licensing process to advance cell and gene therapies. Additionally, the JV can request up to €32 million in grants to support development and manufacturing using Orgenesis Mobile Processing Units. The initiative aims to enhance access to affordable therapies targeting serious diseases in Greece.
Orgenesis (NASDAQ: ORGS) has formed a collaboration with Tel Aviv Sourasky Medical Center to establish a point-of-care cell therapy center at Ichilov Hospital, Israel. The agreement focuses on advancing clinical development and validation of Orgenesis’ CD19 CAR-T therapies, including CAR-T derived exosome products. The partnership will utilize Orgenesis' Mobile Processing Units and Labs (OMPULs) to support research and validation activities, aiming to reduce therapy production costs and accelerate clinical development at the point of care.
Orgenesis reported significant financial growth for Q3 2021, with revenue rising to $28.6 million compared to $5.3 million in Q3 2020. The CEO emphasized the advancement of their POCare Platform, designed to address industry challenges like capacity and cost. The company is expanding its global network, collaborating with top institutions to integrate over 30 therapies in areas such as immuno-oncology and auto-immune diseases. A conference call to discuss these developments is scheduled for 8:30 AM ET today.
Orgenesis Inc (NASDAQ: ORGS) announced a conference call scheduled for 8:30 AM ET on November 4, 2021, to discuss corporate progress and recent developments. The call can be accessed via telephone or through a webcast. A replay will be available post-call on the Company’s Investor Events website. Orgenesis specializes in cell and gene therapies, leveraging its POCare Platform to deliver affordable and accessible treatment solutions at the point of care. This framework includes licensed therapeutics, automated technology systems, and a collaborative network aimed at enhancing patient care.
Orgenesis (NASDAQ: ORGS) has partnered with Savicell Diagnostics to enhance its cell and gene therapy platform. This collaboration aims to develop diagnostic kits for quality control and monitoring, new assays to boost potency, and companion diagnostics for patient targeting. Orgenesis gains exclusive rights to use and sell Savicell’s ImmunoBiopsy™ technology, initially focusing on lung cancer. This partnership seeks to increase the efficacy of therapies and ensure consistency in manufacturing processes, representing a significant advancement in Orgenesis' mission to innovate in the biotech sector.
Orgenesis Inc. (NASDAQ:ORGS) will present at the SNN Network Summer Virtual Event 2021 on August 19, 2021, at 8:00 AM ET. CEO Vered Caplan will lead the presentation and engage with investors. The event is accessible via webcast and requires registration for 1x1 investor meetings. Recorded webcasts will also be available afterward. Orgenesis focuses on cell and gene therapies, utilizing its POCare Platform for efficient, decentralized production and improved patient access.